Health AI: A New Era for Patient Care as Avant Technologies Expands Its Reach
USA News Group News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, Jan. 17, 2025 /PRNewswire/ — Experts suggest that artificial intelligence (AI) will soon transition from being a novelty in healthcare to an essential tool. With over 800 FDA-cleared health AI applications, the expectation is that AI will significantly transform the industry. A recent article from Fast Company predicts that by 2025, health AI will encompass home testing, AI agents, passive monitoring, ambient documentation, and autonomous coding. Additionally, the World Economic Forum is emphasizing how generative AI could enhance clinical trials. A survey from eClinicalWorks reveals that 90% of healthcare professionals have a positive outlook on AI. Driving this innovation are companies like Avant Technologies, Inc. AVAI, Recursion Pharmaceuticals, Inc. RXRX, Teladoc Health, Inc. TDOC, Butterfly Network, Inc. BFLY, and Absci Corporation ABSI.
Analysts from market.us forecast that the Generative AI in Healthcare Market will soar to US$17.2 billion by 2032, with a compound annual growth rate (CAGR) of 37%. Meanwhile, researchers at Technavio predict an even more robust future, estimating that the Smart Healthcare Market—which includes telemedicine, mHealth, smart pills, and AI—will expand by US$125.7 billion by 2028.
Avant Technologies Collaborates with Ainnova to Enhance Disease Detection
Avant Technologies, Inc. AVAI has announced a partnership with Ainnova Tech, Inc. (Ainnova), a healthcare technology firm committed to innovating early disease detection through AI. Ainnova has secured an exclusive license for four advanced AI-driven algorithms from one of Asia’s
The newly acquired algorithms focus on the early detection of cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease. These tools will leverage Ainnova’s sophisticated AI platform, VisionAI, to efficiently and accurately identify early signs of these conditions.
This exclusive licensing agreement will provide Ainova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, with a robust foundation for enhancing patient care in the United States through effective risk screening.
Ainnova plans to roll out these innovative solutions in Latin America in collaboration with strategic partners across key markets such as Mexico and Brazil. AAC aims to build on Ainnova’s growth by obtaining clearance from the U.S. Food and Drug Administration (FDA) in 2025 to launch these solutions in the U.S.
“This license represents a pivotal moment for Ainnova and its partnership with Avant as it enables us to deliver world-class, proven solutions to the Americas,” stated Vinicio Vargas, CEO of Ainnova. “It not only enhances our portfolio but also aligns with our ongoing research and development initiatives to expand the range of diseases detectable quickly and affordably. We’re dedicated to advancing preventive care and making healthcare accessible to all.”
CONTINUED… Read this and more updates for Avant Technologies Inc.https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry updates include:
Recursion Pharmaceuticals, Inc. RXRX, a clinical-stage biotechnology firm, has recently merged with Exscientia and reported initial monotherapy results…
REC-617 Shows Promise in Treating Advanced Solid Tumors
Recent findings from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, indicate that it is well-tolerated across various dosages (2-20 mg QD and 1 mg BID). The most reported side effects were mild (Grade 1-2) and reversible. Remarkably, one patient suffering from metastatic, platinum-resistant ovarian cancer saw a confirmed durable partial response that lasted over 6 months. Additionally, four other participants maintained stable disease for as long as 6 months.
“These initial findings for REC-617 are an encouraging step in the development of CDK7 inhibitors, with a favorable PK/PD profile and notable responses in a heavily pre-treated patient population,” stated Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer of Recursion. “Developed through our AI-powered OS platform, REC-617 underscores our commitment to improving treatment options for patients. We look forward to advancing this initiative in dose escalation and starting the next program phase next year.”
Teladoc Health Unveils Innovative AI Features
Teladoc Health, Inc. TDOC, a leader in virtual care, has launched enhanced AI capabilities for its Virtual Sitter solution. This aims to boost patient safety, address workforce challenges, and improve care delivery for hospitals and health systems. The new AI functions allow one remote staff member to monitor a larger number of patients, increasing inpatient team capacity by 25%. This upgrade complements Teladoc’s array of connected care solutions, which include virtual nursing and physician consults, all while reducing administrative burdens.
“For over a decade, we’ve been at the forefront of integrating technology to assist human interactions in patient care, helping healthcare providers meet their urgent challenges,” said Andy Puterbaugh, President of Hospitals and Health Systems at Teladoc Health. “The incorporation of AI is enhancing our impact and fostering continuous improvements in our comprehensive suite of connected care solutions, such as Virtual Sitter.”
Butterfly Network Launches Educational App for Cardiac Care
Butterfly Network, Inc. BFLY, known for its portable ultrasound technology, has teamed up with HeartFocus, an AI-driven heart echo software provider, to launch the HeartFocus Education app. This app is designed to employ AI for self-paced learning, enabling healthcare practitioners to master ten critical cardiac views accurately within hours. Officially introduced at ANCC MagPath 2024, it integrates seamlessly with Butterfly iQ3 and iQ+ probes operating on iOS iPads.
“HeartFocus stands to significantly enhance cardiac care, and we are excited to collaborate on this innovative educational tool,” remarked Darius Shahida, Chief Strategy Officer at Butterfly Network. “By combining our state-of-the-art ultrasound technology with HeartFocus’s AI-based training, we are paving the way for more healthcare providers to deliver timely and essential diagnostics.”
Absci Corporation Highlights Drug Development Progress
Absci Corporation ABSI, a company focused on generative AI drug development, has shared updates on its proprietary Drug Creation pipeline and showcased breakthroughs via its AI Integrated Drug Creation™ platform. This was presented at Absci’s 2024 R&D Day, highlighting the potential of various therapeutic candidates.
“We are eager to present our target opportunities for ABS-201 and share new data on ABS-101 and ABS-301, alongside the introduction of ABS-501 to our pipeline,” said Sean McClain, Founder and CEO of Absci. “ABS-201, targeted at treating male and female pattern hair loss, could create a valuable new market given the significant unmet clinical needs. As we approach the end of 2024, we anticipate reaching multiple milestones in our project portfolio and maintaining partnerships within the pharma sector.”
Source: USA News Group
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: This publication does not offer personalized financial advice. Consult a licensed financial advisor before making any investment decisions. This is a paid advertisement. USA News Group is a subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has received compensation for advertising from Avant Technologies Inc. This could present a conflict of interest. Please conduct your own research for any investment considerations.
Source: PR Newswire
SOURCE USA News Group
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
